Sannuo Biotech released its 2026 semi-annual report, achieving operating revenue of 2.537 billion yuan, up 12.08% year-on-year. Net profit attributable to shareholders of the listed company was 221 million yuan, up 22.52% year-on-year. The company plans not to distribute cash dividends, bonus shares, or convert capital reserve into share capital. Second-quarter net profit was 124 million yuan, up 26% quarter-on-quarter from 98 million yuan in the first quarter.
Sinocare IncSannuo Biotech's net profit up 22.52% year-on-year in H1 2026, indicating strong earnings growth.